* Arcutis Biotherapeutics Inc ARQT.OQ reported a quarterly
adjusted loss of 42 cents per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of $-1.16. The mean expectation of six analysts
for the quarter was for a loss of 52 cents per share. Wall
Street expected results to range from -56 cents to -45 cents per
share.
* Revenue rose 494.6% to $30.86 million from a year ago;
analysts
expected $29.08 million.
* Arcutis Biotherapeutics Inc's reported EPS for the quarter
was a
loss of 42 cents.
* The company reported a quarterly loss of $52.33 million.
* Arcutis Biotherapeutics Inc shares had risen by 7.0% this
quarter and gained 208.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 11.4%
in the last three months.
* In the last 30 days, two analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Arcutis
Biotherapeutics Inc is $19.00
This summary was machine generated from LSEG data August 15 at
04:34 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.52 -0.42 Beat
Mar. 31 2024 -0.73 -0.32 Beat
Dec. 31 2023 -0.77 -0.72 Beat
Sep. 30 2023 -0.86 -0.73 Beat